Xenon Pharmaceuticals XENE Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0-100% | $7.5M— | $7.5M— | $7.5M— | $7.5M— | ||
| $328.25M+44.4% | $300.94M+43.0% | $272.71M+42.0% | $252.63M+42.0% | $227.34M+32.0% | ||
| $84.41M+15.4% | $79.63M+15.6% | $75.57M+19.0% | $72.99M+22.4% | $73.15M+41.2% | ||
| $412.66M+37.3% | $380.57M+36.3% | $348.28M+36.3% | $325.62M+37.1% | $300.5M+34.1% | ||
| -$412.66M-40.8% | -$373.07M-33.6% | -$340.78M-33.4% | -$318.12M-33.9% | -$293M-30.8% | ||
| $27.51M-26.6% | $28.18M-31.1% | $31.08M-25.4% | $35.53M-7.0% | $37.48M+6.2% | ||
| -$385.15M-50.7% | -$344.89M-44.7% | -$309.7M-44.8% | -$282.6M-41.8% | -$255.52M-35.4% | ||
| -$1.98M+51.4% | $1.02M+125% | -$3.37M-656% | -$4.37M-1,443% | -$4.07M-2,296% | ||
| -$383.17M-52.4% | -$345.91M-47.6% | -$306.33M-43.6% | -$278.23M-39.8% | -$251.45M-33.3% | ||
| -$4.70-45.5% | -$4.36-44.4% | -$3.89-37.9% | -$3.55-29.6% | -$3.23-19.2% | ||
| -$410.19M-41.3% | -$370.53M-33.9% | -$338.18M— | -$315.5M— | -$290.36M— | ||
| -$412.66M-40.8% | -$373.07M-33.6% | -$340.78M-33.4% | -$318.12M-33.9% | -$293M-30.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Xenon Pharmaceuticals profitable?
- Xenon Pharmaceuticals is not currently profitable: it reported a net loss of $383.2M over the trailing twelve months, a -4612.1% net margin.
- What is Xenon Pharmaceuticals's earnings per share?
- Xenon Pharmaceuticals's diluted EPS over the trailing twelve months is $-4.70.
- Where does Xenon Pharmaceuticals's income statement data come from?
- Every line is extracted from Xenon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.